U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare and Medicaid Services Mehmet Oz in the Oval Office in Washington, D.C., U.S., April 18, 2025. REUTERS/Nathan Howard/File Photo

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The Washington Post reports.

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is planning a five-year experiment under which Americans on Medicare and Medicaid could get access to expensive weight loss drugs.